Publicacións nas que colabora con Carlos Spuch Calvar (20)

2024

  1. Characterization and modulation of voltage-gated potassium channels in human lymphocytes in schizophrenia

    Schizophrenia Research, Vol. 270, pp. 260-272

2023

  1. Human Breast Milk microRNAs, Potential Players in the Regulation of Nervous System

    Nutrients, Vol. 15, Núm. 14

  2. Proteomic analysis of exosomes derived from human mature milk and colostrum of mothers with term, late preterm, or very preterm delivery

    Analytical Methods, Vol. 15, Núm. 37, pp. 4905-4917

2022

  1. Changes in the Brain Extracellular Matrix Composition in schizophrenia: A Pathophysiological Dysregulation and a Potential Therapeutic Target

    Cellular and Molecular Neurobiology, Vol. 42, Núm. 6, pp. 1921-1932

  2. Efficacy and Safety of Lithium Treatment in SARS-CoV-2 Infected Patients

    Frontiers in Pharmacology, Vol. 13

  3. Efficacy of the Therapeutic Game “Trisquel” in the Treatment of Patients With Substance-Related Disorders Randomized Clinical Study

    Frontiers in Psychiatry, Vol. 13

2021

  1. Important role of microglia in HIV-1 associated neurocognitive disorders and the molecular pathways implicated in its pathogenesis

    Annals of Medicine, Vol. 53, Núm. 1, pp. 43-69

  2. Proteomic and metabolic profiling of chronic patients with schizophrenia induced by a physical activity program: Pilot study

    Revista de Psiquiatria y Salud Mental, Vol. 14, Núm. 3, pp. 125-138

  3. The role of the second extracellular loop of norepinephrine transporter, neurotrophin-3 and tropomyosin receptor kinase C in T cells: A peripheral biomarker in the etiology of schizophrenia

    International Journal of Molecular Sciences, Vol. 22, Núm. 16

  4. Voices 2: Improving Prosodic Recognition in Schizophrenia With an Online Rehabilitation Program

    Frontiers in Psychology, Vol. 12

2020

  1. A Systematic Review of Efficacy, Safety, and Tolerability of Duloxetine

    Frontiers in Psychiatry, Vol. 11

  2. Brainwaves Oscillations as a Potential Biomarker for Major Depression Disorder Risk

    Clinical EEG and Neuroscience, Vol. 51, Núm. 1, pp. 3-9

  3. Does Lithium Deserve a Place in the Treatment Against COVID-19? A Preliminary Observational Study in Six Patients, Case Report

    Frontiers in Pharmacology, Vol. 11

  4. Mania as Debut of Cushing's Syndrome

    Case Reports in Psychiatry, Vol. 2020

  5. Plasma β-III tubulin, neurofilament light chain and glial fibrillary acidic protein are associated with neurodegeneration and progression in schizophrenia

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Proteomics in Schizophrenia: A Gateway to Discover Potential Biomarkers of Psychoneuroimmune Pathways

    Frontiers in Psychiatry, Vol. 10

2018

  1. Cytokines dysregulation in schizophrenia: A systematic review of psychoneuroimmune relationship

    Schizophrenia Research, Vol. 197, pp. 19-33

  2. The neurobiological hypothesis of neurotrophins in the pathophysiology of schizophrenia: A meta-analysis

    Journal of Psychiatric Research, Vol. 106, pp. 43-53

  3. The role of the gut microbiota in schizophrenia: Current and future perspectives

    World Journal of Biological Psychiatry, Vol. 19, Núm. 8, pp. 571-585

2017

  1. Schizophrenia: A review of potential biomarkers

    Journal of Psychiatric Research, Vol. 93, pp. 37-49